The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...

Achieved 98% manufacturing batch success rate at BaseCamp across cell therapy, viral vector, and mRNA– Positioned U.S.-based biomanufacturing ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s ...

The College of Southern Maryland received a $100,000 donation from the Wills Group to launch a radiation therapy program in fiscal year 2027, addressing a 13 percent national vacancy rate and regional ...

Cryotherapy Market OverviewThe Cryotherapy Market is projected to grow at a rate of around 7% by 2028, driven by rising incidences of sports injuries and cancer, continuous technological advancements, ...

By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

What is cervical cancer, and how can screening and HPV vaccination prevent it? Learn why early detection makes a life-saving ...

YD BioMed expects to advance two lead ophthalmology programs utilizing its LSC Exosome platform, each supported by targeted regulatory and clinical milestones, which the timing of these milestones ...

Scientists are developing magnetically driven nanorobots that can actively navigate the bloodstream and deliver chemotherapy ...

One group lauding the cuts is the National Rifle Association, which commended the Trump administration in November for ...

True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...